This study will compare a nucleoside reverse transcriptase inhibitor-sparing (NRTI-sparing)
regimen (Kaletra + nevirapine) to two nucleoside reverse transcriptase inhibitor-based
regimens (Combivir + nevirapine and Combivir + Kaletra).
Participants will be randomly assigned to receive one of the following drug combinations:
- lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;
- Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;
- Combivir and lopinavir/ritonavir twice a day.
Phase:
Phase 4
Details
Lead Sponsor:
University of British Columbia
Collaborators:
Abbott Boehringer Ingelheim CIHR Canadian HIV Trials Network